{"id":"placebo-matching-ipilimumab","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1789844","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T12:28:31.491266","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"In clinical trials, placebo matching ipilimumab is used as a control to maintain blinding while patients receive an inert substance with identical appearance and administration schedule to ipilimumab (a CTLA-4 inhibitor). This allows for proper assessment of ipilimumab's true efficacy by comparing outcomes against a blinded control rather than open-label or unblinded comparisons.","oneSentence":"This is a placebo control arm matching the dosing and administration schedule of ipilimumab, the active comparator.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:50.926Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trials of ipilimumab-based immunotherapy regimens"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT03937219","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2019-06-25","conditions":"Renal Cell Carcinoma","enrollment":855},{"nctId":"NCT01844505","phase":"PHASE3","title":"Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-06-11","conditions":"Unresectable or Metastatic Melanoma","enrollment":945},{"nctId":"NCT02388906","phase":"PHASE3","title":"Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-03-16","conditions":"Melanoma","enrollment":906},{"nctId":"NCT03409614","phase":"PHASE3","title":"Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-03-06","conditions":"Non-small Cell Lung Cancer","enrollment":790},{"nctId":"NCT01927419","phase":"PHASE2","title":"Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-08-23","conditions":"Unresectable Melanoma, Metastatic Melanoma","enrollment":142},{"nctId":"NCT01450761","phase":"PHASE3","title":"Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12-13","conditions":"Small Cell Lung Carcinoma","enrollment":1351},{"nctId":"NCT00527735","phase":"PHASE2","title":"Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-02","conditions":"Lung Cancer, Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung","enrollment":334}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching Ipilimumab","genericName":"Placebo matching Ipilimumab","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Biologic","firstApprovalDate":"","aiSummary":"This is a placebo control arm matching the dosing and administration schedule of ipilimumab, the active comparator. Used for Control arm in phase 3 clinical trials of ipilimumab-based immunotherapy regimens.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}